What are the risks of combining mirtazapine (Remeron) with trazodone?

Risk of Combining Mirtazapine (Remeron) and Trazodone

Combining mirtazapine and trazodone is generally considered safe based on clinical experience, though it carries specific risks that require monitoring, particularly for excessive sedation and serotonin syndrome.

Primary Risks to Monitor

1. Excessive Sedation and CNS Depression

Both medications have significant sedative properties, and their combination creates an additive effect on psychomotor performance and daytime functioning 1. The FDA label for Remeron explicitly warns to "avoid taking medicines used to treat anxiety, insomnia, and seizures...during treatment" and notes "additive effect on psychomotor performance with concomitant CNS depressants" 2.

Practical implications:

• Patients should not drive or operate machinery until effects are known
• Start with lower doses of each medication
• Monitor for excessive daytime sleepiness, impaired coordination, and falls (especially in elderly patients)
• Avoid alcohol completely during treatment

2. Serotonin Syndrome Risk

While both drugs are serotonergic, the risk of serotonin syndrome exists but appears relatively low when these two agents are combined 2. The FDA label lists trazodone among "other serotonergic drugs" that increase serotonin syndrome risk when combined with mirtazapine 2.

Warning signs requiring immediate medical attention:

• Agitation, confusion, or delirium
• Fast heart rate, blood pressure changes
• Tremors, muscle rigidity, or twitching
• High fever (hyperthermia)
• Seizures
• Nausea, vomiting, diarrhea

3. Cardiovascular Effects

Both medications can affect cardiac rhythm. The combination may increase risk of:

• QT prolongation and arrhythmias (including Torsades de Pointes reported with mirtazapine) 1
• Orthostatic hypotension (particularly with trazodone)
• Dizziness and syncope

Clinical Context Supporting This Combination

Despite these risks, clinical guidelines acknowledge this combination has utility in specific situations 1:

The 2008 AASM insomnia guideline states: "No research studies have been conducted to specifically examine such combinations, but a wealth of clinical experience with the co-administration of these drugs suggests the general safety and efficacy of this combination" 1.

The guideline further notes: "A combination of medications from two different classes may improve efficacy by targeting multiple sleep-wake mechanisms while minimizing the toxicity that could occur with higher doses of a single agent" 1.

When This Combination May Be Appropriate:

• Treatment-resistant depression with prominent insomnia 3
• When a single sedating antidepressant at higher doses causes unacceptable side effects
• Comorbid depression and anxiety with severe sleep disturbance
• As part of a sequential treatment algorithm when initial monotherapy fails 1

A 2016 case report demonstrated successful use of trazodone added to paroxetine and mirtazapine in treatment-resistant depression, though this represents triple antidepressant therapy 3.

Monitoring Requirements

If this combination is prescribed, implement the following:

1. Start low, go slow: Use the lowest effective doses of each medication
2. Regular follow-up: Every few weeks initially to assess effectiveness and side effects 1
3. Patient education on:
   • Serotonin syndrome warning signs
   • Fall risk and avoiding activities requiring alertness
   • Absolute avoidance of alcohol
   • Not combining with benzodiazepines or other sedatives
4. Monitor for:
   • Excessive daytime sedation
   • Orthostatic vital signs (especially in elderly)
   • Cognitive impairment or confusion
   • Weight gain (both drugs increase appetite) 4

Special Populations

Elderly Patients

Exercise particular caution - both medications require dose reduction in older adults 1:

• Higher risk of falls, confusion, and hyponatremia
• Increased sensitivity to sedative effects
• Greater risk of orthostatic hypotension

Patients with Respiratory Compromise

Use with extreme caution or avoid in patients with:

• Sleep apnea
• COPD
• Asthma
• Hepatic or heart failure 1

A 2021 study found that trazodone combined with oxycodone significantly increased respiratory depression in rats, suggesting caution with any CNS depressant combinations 5.

Common Pitfalls to Avoid

1. Don't assume safety without monitoring - even though clinical experience suggests general safety, individual responses vary
2. Don't ignore pharmacokinetic interactions - mirtazapine is metabolized by CYP3A4, CYP2D6, and CYP1A2; check for other interacting medications 2
3. Don't combine with MAOIs - mirtazapine is contraindicated within 14 days of MAOI use 2
4. Don't overlook the need for cognitive-behavioral therapy - medications should be supplemented with behavioral interventions when possible 1

Bottom Line

This combination can be used safely with appropriate monitoring, particularly when treating comorbid depression and insomnia that hasn't responded to monotherapy. The primary risks are excessive sedation and theoretical serotonin syndrome, both of which are manageable with proper patient selection, dose titration, and monitoring. The combination leverages complementary mechanisms while potentially avoiding the need for higher doses of a single agent.